Neuroendocrine prostate cancer after hormonal therapy: Knowing is half the battle

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3360-3364

  Tagawa, Scott T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; BICALUTAMIDE; DOCETAXEL; LEUPRORELIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; RADIOGRAPHY; TREATMENT FAILURE; ADENOCARCINOMA; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; MALE; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS;

EID: 84908347287     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.5100     Document Type: Article

References (24)

1. Aparicio A, Logothetis CJ, Maity SN: Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1:466-468, 2011
2. Beltran H, Tomlins S, Aparicio A, et al: Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20:2846-2850, 2014
3. Beltran H, Tagawa ST, Park K, et al: Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 30:e386-e389, 2012
4. Shen R, Dorai T, Szaboles M, et al: Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormonedepleted medium. Urol Oncol 3:67-75, 1997
5. Terry S, Beltran H: The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60, 2014
6. Lapuk AV, Wu C, Wyatt AW, et al: From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 227:286-297, 2012
7. Terry S, Maillé P, Baaddi H, et al: Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia 15:761-772, 2013
8. Logothetis CJ, Gallick GE, Maity SN, et al: Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer. Cancer Discov 3:849-861, 2013
9. Tagawa ST, Akhtar NH, Robinson BD, et al: Uncommon cancers of the prostate, in Raghavan D, Blanke CD, Johnson DH, et al (eds): Textbook of Uncommon Cancer (ed 4). Hoboken, NJ, Wiley & Sons, 2012, pp 47-76
10. Aparicio AM, Harzstark AL, Corn PG, et al: Platinum-based chemotherapy for variant castrateresistant prostate cancer. Clin Cancer Res 19:3621-3630, 2013
11. Raines D, Chester M, Diebold AE, et al: A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 41:508-511, 2012
12. Wang HT, Yao YH, Li BG, et al: Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: Factors associated with time to development of NEPC and survival from NEPC diagnosis-A systematic review and pooled analysis. J Clin Oncol 32:3383-3390, 2014
13. Epstein JI, Amin MB, Beltran H, et al: Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-767, 2014
14. Beltran H, Rickman DS, Park K, et al: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487-495, 2011
15. Mosquera JM, Beltran H, Park K, et al: Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15:1-10, 2013
16. Beltran H, Yelensky R, Frampton GM, et al: Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63: 920-926, 2013
17. Tzelepi V, Zhang J, Lu JF, et al: Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18:666-677, 2012
18. Aparicio A, Tzelepi V, Araujo JC, et al: Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 71:846-856, 2011
19. Tan HL, Sood A, Rahimi HA, et al: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20:890-903, 2014
20. Meulenbeld HJ, Bleuse JP, Vinci EM, et al: Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 111:44-52, 2013
21. Beltran H, Rubin MA, Mosquera JM, et al: A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. J Clin Oncol 31, 2013 (suppl 15s; abstr TPS5096).
22. Galanis E, Frytak S, Lloyd RV: Extrapulmonary small cell carcinoma. Cancer 79:1729-1736, 1997
23. Papandreou CN, Daliani DD, Thall PF, et al: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080, 2002
24. Fléchon A, Pouessel D, Ferlay C, et al: Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castrationresistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 22:2476-2481, 2011.